Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Huntsman

Showing results (51-60 of 141) with videos related to

Pageof 15
Sort By:
Cancer Research Communications|January 9, 2025
Evaluating Ovarian Cancer Risk-Reducing Salpingectomy Acceptance: A SurveyAlexandra Lukey, Ramlogan Sowamber, David Huntsman, et al.
The Journal of Pathology|December 8, 2009
Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinomaJason Madore, Fengge Ren, Ali Filali-Mouhim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 13, 2008
Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancersStephen Chia, Brian Norris, Caroline Speers, et al.
Experimental Cell Research|August 23, 2005
Loss of functional E-cadherin renders cells more resistant to the apoptotic agent taxol in vitroPaulo Ferreira, Maria José Oliveira, Eliana Beraldi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 28, 2006
Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic IndexGrace M Callagy, Paul D Pharoah, Sarah E Pinder, et al.
Scientific Reports|October 11, 2016
Dies1/VISTA expression loss is a recurrent event in gastric cancer due to epigenetic regulationPatrícia Oliveira, Joana Carvalho, Sara Rocha, et al.
Plos One|October 3, 2009
MicroRNA profiling of BRCA1/2 mutation-carrying and non-mutation-carrying high-grade serous carcinomas of ovaryCheng-Han Lee, Subbaya Subramanian, Andrew H Beck, et al.
The American Journal of Pathology|February 19, 2013
The chromatin remodeling gene ARID1A is a new prognostic marker in clear cell renal cell carcinomaZsuzsanna Lichner, Andreas Scorilas, Nicole M A White, et al.
Human Mutation|April 23, 2002
Screening E-cadherin in gastric cancer families reveals germline mutations only in hereditary diffuse gastric cancer kindredCarla Oliveira, Maria Cristina Bordin, Nicola Grehan, et al.
Human Molecular Genetics|September 23, 2003
E-cadherin germline missense mutations and cell phenotype: evidence for the independence of cell invasion on the motile capabilities of the cellsGianpaolo Suriano, Maria José Oliveira, David Huntsman, et al.
Pageof 15

Showing results (51-60 of 141) with videos related to

Sort By:
Pageof 15
Cancer Research Communications|January 9, 2025
Evaluating Ovarian Cancer Risk-Reducing Salpingectomy Acceptance: A SurveyAlexandra Lukey, Ramlogan Sowamber, David Huntsman, et al.
The Journal of Pathology|December 8, 2009
Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinomaJason Madore, Fengge Ren, Ali Filali-Mouhim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 13, 2008
Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancersStephen Chia, Brian Norris, Caroline Speers, et al.
Experimental Cell Research|August 23, 2005
Loss of functional E-cadherin renders cells more resistant to the apoptotic agent taxol in vitroPaulo Ferreira, Maria José Oliveira, Eliana Beraldi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 28, 2006
Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic IndexGrace M Callagy, Paul D Pharoah, Sarah E Pinder, et al.
Scientific Reports|October 11, 2016
Dies1/VISTA expression loss is a recurrent event in gastric cancer due to epigenetic regulationPatrícia Oliveira, Joana Carvalho, Sara Rocha, et al.
Plos One|October 3, 2009
MicroRNA profiling of BRCA1/2 mutation-carrying and non-mutation-carrying high-grade serous carcinomas of ovaryCheng-Han Lee, Subbaya Subramanian, Andrew H Beck, et al.
The American Journal of Pathology|February 19, 2013
The chromatin remodeling gene ARID1A is a new prognostic marker in clear cell renal cell carcinomaZsuzsanna Lichner, Andreas Scorilas, Nicole M A White, et al.
Human Mutation|April 23, 2002
Screening E-cadherin in gastric cancer families reveals germline mutations only in hereditary diffuse gastric cancer kindredCarla Oliveira, Maria Cristina Bordin, Nicola Grehan, et al.
Human Molecular Genetics|September 23, 2003
E-cadherin germline missense mutations and cell phenotype: evidence for the independence of cell invasion on the motile capabilities of the cellsGianpaolo Suriano, Maria José Oliveira, David Huntsman, et al.
Pageof 15